Form 4: Corcept Therapeutics Executive Hazel Hunt Reports Stock Option Exercise and Share Disposal

Hazel Hunt, Chief Scientific Officer of Corcept Therapeutics, exercised stock options and disposed of shares to cover the exercise price and tax obligations.

Summary

• On February 11, 2025, Hazel Hunt, the Chief Scientific Officer of Corcept Therapeutics, exercised stock options to acquire 150,000 shares of common stock at a price of $3.29 per share.
• Simultaneously, Hunt disposed of 85,176 shares at $68.11 per share to cover the exercise price and withholding taxes related to the option exercise.
• Following these transactions, Hunt directly owns 183,405 shares of Corcept Therapeutics common stock.
• The stock options exercised were fully exercisable and were set to expire on February 18, 2025.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard transaction related to executive compensation and doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

This filing is a routine disclosure of insider transactions, which are common occurrences in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Key Dates

Keywords

Form 4, Insider Trading, Stock Options, Corcept Therapeutics, CORT, Hazel Hunt, Executive Compensation, Beneficial Ownership